Kramer Robin 4

What Happened
Robin Kramer, a director of Armata Pharmaceuticals (ARMP), was granted a derivative award for 25,640 shares on March 9, 2026. The reported acquisition price is $0.00 (i.e., a stock option award), so no cash was exchanged in the filing.

Key Details

• Transaction date: 2026-03-09; filing received: 2026-03-11 (filed within the typical 2-business-day Form 4 window).
• Security: derivative award (stock options) for 25,640 shares; reported price: $0.00; reported value: $0.
• Shares owned after transaction: not specified in the reported Form 4.
• Footnote: The stock options will vest in full on March 9, 2027, subject to continuous service through that date (Footnote F1).
• No 10b5-1 plan, tax withholding, or immediate sale indicated in the filing.

Context
This is a compensation-related equity grant (an award of options) rather than an open-market buy or sale. Such grants are common for directors and are not direct indicators of short-term trading intent. The options vest in one year, so they are locked until the 2027 vesting date assuming continued service.